Holen Sie sich die Stockscreener-App
30.42
1.54%
0.42
Schlusskurs vom Vortag:
$30.00
Offen:
$30.58
24-Stunden-Volumen:
13,176
Relative Volume:
0.01
Marktkapitalisierung:
$3.95B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-507.65M
KGV:
-6.613
EPS:
-4.6
Netto-Cashflow:
$-616.24M
1W Leistung:
-7.69%
1M Leistung:
-15.22%
6M Leistung:
-63.67%
1J Leistung:
-60.55%
1-Tages-Spanne:
$30.37
$30.58
1-Wochen-Bereich:
$29.08
$31.50
52-Wochen-Spanne:
$27.66
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650-837-0111
Adresse
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Vergleichen Sie PCVX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
30.41 | 3.85B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.21 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.90 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
639.41 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
298.32 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Eingeleitet | Goldman | Buy |
| 2023-12-07 | Eingeleitet | Mizuho | Buy |
| 2023-04-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-03 | Bestätigt | Needham | Buy |
| 2022-12-15 | Eingeleitet | Guggenheim | Buy |
| 2022-11-17 | Eingeleitet | BTIG Research | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-24 | Fortgesetzt | Jefferies | Buy |
| 2020-07-07 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Vaxcyte Inc. Rebounds From Oversold Zone — Now WhatTriple Digit Growth Focused Trade Plan Reviewed - 선데이타임즈
Vaxcyte Reports Progress in Vaccine Development - TipRanks
Guggenheim lowers Vaxcyte stock price target to $116 on trial timeline shifts - Investing.com Canada
Vaxcyte’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Vaxcyte, Inc. shares fall 9.56% intraday after FDA interactions and Phase 3 clinical program finalization. - AInvest
Vaxcyte price target lowered to $50 from $85 at TD Cowen - TipRanks
Vaxcyte’s Strategic Adjustments and Optimized Trials Drive Buy Rating - TipRanks
Vaxcyte Q2 Loss Widens 11%, Ends Quarter with $2.83B in Cash - AInvest
Vaxcyte Q2 EPS $1.22, beats consensus $1.16; CEO discusses Phase 3 program for VAX-31. - AInvest
Vaxcyte (PCVX) Q2 Loss Widens 11% - AOL.com
Vaxcyte (PCVX) Q2 Loss Widens 11% - The Motley Fool
Promising Prospects for Vaxcyte’s VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating - TipRanks
Vaxcyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vaxcyte Reports Second Quarter 2025 Financial Results and - GlobeNewswire
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) - Yahoo Finance
MACD Signals Flash Warning for Vaxcyte Inc. StockMulti-Bagger Potential Stock Forecast Tools Released - metal.it
What is the dividend policy of Vaxcyte Inc. stockStay ahead with advanced stock screening tools - Jammu Links News
How strong is Vaxcyte Inc. company’s balance sheetUnprecedented profits - Jammu Links News
How does Vaxcyte Inc. compare to its industry peersDiscover stocks with explosive upside potential - Jammu Links News
Is Vaxcyte Inc. stock overvalued or undervaluedAchieve breakthrough performance in the market - Jammu Links News
Is Vaxcyte Inc. a growth stock or a value stockFree Investment Risk Control - Jammu Links News
How does Vaxcyte Inc. generate profit in a changing economyAchieve rapid financial growth with smart picks - Jammu Links News
When is Vaxcyte Inc. stock expected to show significant growthUnlock powerful stock screening tools today - Jammu Links News
Is it the right time to buy Vaxcyte Inc. stockDiscover stocks with explosive growth potential - Jammu Links News
What drives Vaxcyte Inc. stock priceInvest smarter with real-time trading signals - Jammu Links News
What are the latest earnings results for Vaxcyte Inc.Stay ahead with advanced stock screening tools - Jammu Links News
What are analysts’ price targets for Vaxcyte Inc. in the next 12 monthsBuild a diversified portfolio for steady growth - Jammu Links News
Should I hold or sell Vaxcyte Inc. stock in 2025Phenomenal capital appreciation - Jammu Links News
What institutional investors are buying Vaxcyte Inc. stockPowerful profit generation - Jammu Links News
InvestingPro’s Fair Value model predicted Vaxcyte’s 46% decline By Investing.com - Investing.com
Vaxcyte, Inc. (PCVX)’s VAX-24 Achieves Phase 2 Success in Infants - Yahoo Finance
What markets is Vaxcyte Inc. expanding into Is FDUS stock a good long term investment optionFree Stock Target Finder That Work - Jammu Links News
11 Best Future Stocks to Buy Now - Insider Monkey
What makes Vaxcyte Inc. stock price move sharplyMarket Entry and Exit Point Tips From Traders - metal.it
What is the risk reward ratio of investing in Vaxcyte Inc. stockInvest smarter with daily stock recommendations - Jammu Links News
What catalysts could drive Vaxcyte Inc. stock higher in 2025Rapid growth trajectories - Jammu Links News
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.12%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):